SRX246
 | |
| Systematic (IUPAC) name | |
|---|---|
| 2(R)-((4-(Piperidin-1-yl)piperidin-1-yl)carbonylmethyl)-2-(3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-1-yl)acetic acid N-((R)-α-methylbenzyl)amide | |
| Clinical data | |
| Identifiers | |
| PubChem | CID 44428551 |
| Chemical data | |
| Formula | C43H48F3N5O5 |
| 771.867 | |
|
SMILES
| |
SRX246 is a small-molecule, centrally-active vasopressin V1A receptor antagonist which is undergoing clinical trials for the treatment of affective and anger disorders. It has been studied in animal models, and has completed a phase I trial.[1] SRX246 is an azetidinone compound and is highly selective for the V1A receptor. It was one of many candidate drugs developed from LY307174 as a lead compound, and was found to penetrate into the brain.
A phase II activity trial of the drug in the treatment of adults with intermittent explosive disorder is ongoing.[2]
See also
References
- ↑ Fabio, KM; Guillon, CD; Lu, SF; Heindel, ND; Brownstein, MJ; Lacey, CJ; Garippa, C; Simon, NG (June 2013). "Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist.". Journal of pharmaceutical sciences 102 (6): 2033–43. PMID 23471831.
- ↑ "Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AVN009)". Retrieved 11 March 2015.
External links
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||